List of Excipients in Branded Drug ERYTHROMYCIN AND BENZOYL PEROXIDE

Generic Drugs Containing ERYTHROMYCIN AND BENZOYL PEROXIDE

Company	Ingredient	NDC	Excipient
Rising Pharma Holdings Inc	erythromycin and benzoyl peroxide	64980-328	ALCOHOL
Rising Pharma Holdings Inc	erythromycin and benzoyl peroxide	64980-328	CARBOMER 940
Rising Pharma Holdings Inc	erythromycin and benzoyl peroxide	64980-328	DOCUSATE SODIUM

What are the Most Frequently-Used Excipients in ERYTHROMYCIN AND BENZOYL PEROXIDE?

# Of NDCs	Excipient
1	ALCOHOL
1	CARBOMER 940
1	DOCUSATE SODIUM

Erythromycin and Benzoyl Peroxide Excipient Strategy and Commercial Opportunities

Last updated: September 8, 2026

Erythromycin 3% and benzoyl peroxide 5% is an established topical acne combination with limited differentiation from the active ingredients alone. The strongest commercial opportunities are in vehicle design, stability, packaging, tolerability, preservative reduction, manufacturing efficiency, and differentiated dispensing formats.

The combination is technically demanding because benzoyl peroxide is an oxidizing agent, erythromycin is chemically sensitive, and both actives must remain uniformly dispersed or dissolved throughout the product shelf life. A commercially successful product therefore depends more on excipient selection and package engineering than on new pharmacology.

What is the commercial profile of erythromycin and benzoyl peroxide?

The combination is used for topical treatment of acne vulgaris. Historical U.S. products include Benzamycin, generally identified as erythromycin 3% and benzoyl peroxide 5% topical gel. The product category has also included separately packaged or user-mixed systems designed to improve erythromycin stability before use.

Attribute	Commercial relevance
Active ingredients	Erythromycin and benzoyl peroxide
Typical topical strengths	Erythromycin 3%; benzoyl peroxide 5%
Primary indication	Acne vulgaris
Dosage form	Topical gel, kit, or separately mixed gel system
Principal technical issue	Oxidative and hydrolytic stability of erythromycin in the presence of benzoyl peroxide
Main differentiation levers	Vehicle, particle size, drying time, irritation, odor, packaging, shelf life, and patient handling
Main competing categories	Benzoyl peroxide monotherapy, topical retinoids, clindamycin combinations, azelaic acid, and fixed-dose retinoid combinations
Prescription status	Product-specific; U.S. regulatory status must be confirmed against current FDA listings

Benzoyl peroxide has strong consumer recognition and broad generic availability. Erythromycin has weaker current differentiation because topical macrolide use is constrained by antimicrobial-resistance concerns and competition from non-antibiotic acne products. A new product therefore needs a clear performance or tolerability advantage.

What excipient problems must a formulation solve?

The central formulation problem is maintaining erythromycin potency while delivering benzoyl peroxide in a cosmetically acceptable topical vehicle.

Erythromycin stability

Erythromycin is vulnerable to degradation under unsuitable pH and moisture conditions. The formulation must control:

• pH and buffer capacity
• Water activity
• Residual moisture
• Exposure to oxygen and light
• Contact time between erythromycin and benzoyl peroxide
• Metal-ion catalysis
• Storage temperature

A fully aqueous system can improve spreadability but may increase chemical and microbiological control requirements. A low-water or anhydrous system can improve stability, but may create problems with grittiness, drying, skin feel, and active uniformity.

Benzoyl peroxide stability

Benzoyl peroxide decomposes through heat, light, moisture, contamination, and catalytic impurities. The excipient package must avoid components that accelerate decomposition or destabilize the emulsion or gel network.

Potentially important controls include:

• Low levels of transition-metal impurities
• Controlled peroxide quality
• Light-protective packaging
• Low processing temperatures
• Defined particle-size distribution
• Controlled shear during dispersion
• Low residual water where compatible with the product design

Compatibility between the actives

Benzoyl peroxide can oxidize susceptible molecules. Erythromycin stability must be demonstrated in the finished product, not inferred from the stability of either active alone. Formulators should evaluate:

• Erythromycin assay and degradation products
• Benzoyl peroxide assay and decomposition products
• Microstructure over time
• Viscosity and yield stress
• Particle-size changes
• Phase separation
• Color and odor
• In-use stability after opening

FDA guidance for topical products emphasizes product quality, critical material attributes, process controls, and performance testing rather than reliance on composition alone (U.S. Food and Drug Administration [FDA], 2022).

Which excipient platforms are most commercially attractive?

Carbomer and neutralized aqueous gels

Carbomer systems are familiar, inexpensive, and easy to manufacture. They can provide acceptable viscosity and patient spreadability. Their weaknesses include possible drying, pilling, tackiness, and sensitivity to neutralization conditions and electrolytes.

Commercial advantages include:

• Low raw-material cost
• Established supplier base
• Simple tube or pump filling
• Familiar regulatory history
• Flexible viscosity adjustment

Development risks include interaction with preservatives, pH drift, and loss of viscosity during accelerated storage.

Hydroalcoholic gels

Alcohol-containing systems can improve drying time and reduce greasy skin feel. They may also support lower water activity. Their principal limitation is irritation, particularly when used with benzoyl peroxide.

These systems may be positioned for patients who prioritize rapid drying and low residue. They are less attractive for sensitive-skin positioning unless the alcohol level is controlled and supported by tolerability data.

Emulsion gels

Emulsion gels can improve moisturization and reduce the harsh sensory profile associated with benzoyl peroxide. They may also improve adherence by reducing tightness and flaking.

The trade-off is greater formulation complexity. Development must control:

• Emulsion droplet size
• Preservative partitioning
• Benzoyl peroxide distribution
• Oxidative stability of oils and surfactants
• Container compatibility
• Long-term viscosity

An emulsion gel may support premium pricing if it delivers measurable improvements in irritation, residue, and cosmetic acceptability.

Anhydrous or low-water systems

Anhydrous systems are commercially attractive where erythromycin stability is the primary barrier. They can reduce hydrolytic degradation and lower the need for conventional aqueous preservation.

Potential disadvantages include:

• Poorer dispersion of hydrophilic excipients
• Higher risk of gritty texture
• More difficult manufacturing
• Increased dependence on suspension stability
• Higher packaging and filling requirements

An anhydrous system may be particularly suitable for a dual-chamber package in which the actives remain separated until dispensing.

Separately packaged or dual-chamber systems

A two-part package can separate erythromycin from benzoyl peroxide until use or reduce the duration of direct contact before application. This architecture may extend shelf life and create a stronger product-specific intellectual-property position.

The commercial disadvantages are patient inconvenience, higher packaging cost, more complex instructions, and potential adherence loss. The system must demonstrate a material benefit over a conventional premixed gel.

What excipients should be screened first?

A practical excipient screen should prioritize compatibility, sensory performance, and regulatory precedent.

Excipient class	Primary function	Key evaluation issue
Carbomers and acrylic polymers	Gel structure	pH sensitivity, tack, viscosity drift
Cellulose polymers	Rheology and suspension	Clarity, microbial control, active uniformity
Polyols	Humectancy and skin feel	Stickiness, water activity, stability
Alcohols	Drying and solvent function	Irritation and flammability
Silicones	Slip and sensory improvement	Dispersion and package compatibility
Emollient esters	Reduced dryness and improved spread	Oxidative stability and acne acceptability
Chelating agents	Metal-ion control	Compatibility and regulatory precedent
Antioxidants	Protection of susceptible excipients	Potential interaction with benzoyl peroxide
Surfactants	Wetting and emulsion formation	Irritation, peroxide decomposition, and preservative partitioning
Preservatives	Microbial protection	Oxidative compatibility and efficacy testing
Buffers and pH adjusters	pH control	Erythromycin stability and skin tolerability

The FDA Inactive Ingredient Database is a starting point for identifying excipients with prior route-specific use, but prior use does not establish compatibility with benzoyl peroxide or erythromycin in the proposed concentration and dosage form (FDA, n.d.-a).

What formulation patents could protect a new product?

The active-ingredient combination is old, so composition-of-matter protection is unlikely to provide a meaningful commercial barrier. Patent value is more likely to arise from a specific formulation or delivery architecture.

Potential formulation claims

A defensible patent program could target:

• A defined low-water gel containing specified polymer and humectant ranges
• A controlled-particle-size benzoyl peroxide dispersion
• A vehicle that limits erythromycin degradation products
• A dual-chamber or separately activated package
• A low-irritation emulsion gel
• A formulation with defined drying-time or residue performance
• A preservative-free or reduced-preservative system
• A composition with a specified pH, viscosity, or water-activity range
• A manufacturing process that produces a stable peroxide dispersion
• A package that reduces light, oxygen, or moisture ingress

Patent strength will depend on unexpected performance data. Broad claims covering erythromycin, benzoyl peroxide, a gel, and a conventional carbomer are likely to face prior-art and obviousness challenges.

Regulatory exclusivity

A new topical formulation could potentially pursue a 505(b)(2) pathway if it relies partly on a previously approved product while introducing a meaningful formulation, delivery, stability, or labeling change. The regulatory strategy would depend on the extent of reliance on listed drugs, the nature of the clinical bridge, and whether the product can be approved without a full standalone development program (FDA, n.d.-b).

A new generic equivalent would generally follow the ANDA pathway if it meets applicable sameness and equivalence requirements. The regulatory burden can increase when the reference product has complex microstructure, unusual packaging, or a kit-based presentation.

What is the Orange Book and patent status of erythromycin-benzoyl peroxide products?

The Orange Book status is product-specific. A sponsor must distinguish among:

• The original listed drug
• Discontinued products
• Current abbreviated applications
• Listed patents
• Pediatric exclusivity
• Product-specific exclusivity
• Reference-listed-drug status

Historical erythromycin and benzoyl peroxide products have been marketed for many years, making early active-ingredient and basic formulation protection unlikely to remain commercially relevant. Current patent risk should be assessed from the FDA Orange Book entry for the selected reference product and from USPTO records for later formulation, package, and process patents (FDA, n.d.-c; U.S. Patent and Trademark Office [USPTO], n.d.).

No patent conclusion should be drawn from the age of the molecule alone. A later patent could still affect a specific formulation, delivery device, or manufacturing process.

When does erythromycin and benzoyl peroxide lose exclusivity?

There is no single expiration date for the combination because exclusivity depends on the specific product and patent family.

Protection type	Likely status for an established combination
Erythromycin composition patent	Expired or commercially irrelevant
Benzoyl peroxide composition patent	Expired
Basic fixed-combination concept	Likely old and vulnerable to prior art
Original formulation patent	Product-specific; requires record review
Later vehicle patent	May remain relevant if claims are narrow and unexpired
Package or device patent	May remain relevant after basic formulation protection
Regulatory exclusivity	Product-specific and generally limited in duration
Trade-secret manufacturing know-how	Can remain relevant without public expiration

A paragraph IV challenge would be relevant only if an ANDA applicant seeks approval before expiration of an Orange Book-listed patent. The challenge would target a listed patent and may trigger litigation, a 30-month stay, or an alternative resolution depending on the statutory and procedural facts (FDA, n.d.-d).

What generic entry risks exist?

Generic entry risk is high for a conventional premixed gel with widely used excipients and no meaningful device complexity. It is lower for:

• Dual-chamber packaging
• In-use mixing systems
• Low-water or anhydrous suspensions
• Complex emulsion gels
• Products with distinctive microstructure
• Formulations supported by narrow but technically strong patents
• Products requiring specialized manufacturing controls

A generic applicant may challenge a formulation patent by arguing that the claimed excipients are conventional, the ranges are obvious, or the stability results are predictable. The innovator’s strongest response is usually comparative data showing unexpected stability, lower irritation, improved active uniformity, or superior in-use performance.

How does the combination compare with competing acne products?

Product category	Main advantage	Main weakness	Excipient opportunity
Benzoyl peroxide alone	No antibiotic-resistance concern	Irritation and dryness	Moisturizing, low-irritation vehicle
Erythromycin alone	Familiar topical antibiotic	Resistance and limited differentiation	Improved tolerability and adherence
Erythromycin/benzoyl peroxide	Combined antibacterial and keratolytic approach	Stability and irritation challenges	Stable, cosmetically elegant delivery
Clindamycin/benzoyl peroxide	Strong established category	Antibiotic stewardship concerns	Reduced irritation and resistance-conscious positioning
Tretinoin combinations	Strong acne efficacy profile	Irritation and light sensitivity	Controlled release and barrier-supportive vehicle
Azelaic acid	Non-antibiotic positioning	Sensory and irritation issues	Improved spreadability and reduced residue

The commercial case for erythromycin and benzoyl peroxide is strongest where a product can improve tolerability, simplify use, or offer a lower-cost alternative to more complex branded combinations.

Which licensing and partnering opportunities are available?

The most attractive partnering targets are companies with:

• Topical dermatology sales forces
• Generic or 505(b)(2) development capability
• Contract manufacturing capacity for semisolids
• Package-development expertise
• Dermatology-focused clinical networks
• Existing acne or anti-infective portfolios

Licensing value may come from a formulation platform rather than from the active combination. A partner may be interested in a stable low-water vehicle, a dual-chamber dispenser, a proprietary emulsion gel, or a manufacturing process that reduces peroxide loss.

The commercial package should include comparative stability, irritation, drying time, residue, active uniformity, microbial limits, and container-closure data. A formulation without head-to-head performance evidence is unlikely to command a substantial upfront payment.

What development strategy offers the best return?

A staged program should proceed as follows:

1. Select the target product profile, including strength, package, shelf life, drying time, and sensory requirements.
2. Screen aqueous, hydroalcoholic, emulsion, low-water, and dual-chamber prototypes.
3. Measure both active ingredients and degradation products under accelerated and long-term conditions.
4. Test package interaction, light protection, oxygen transmission, and in-use stability.
5. Compare irritation and cosmetic acceptability against an established marketed comparator.
6. Determine whether the regulatory route is ANDA, 505(b)(2), or a new-drug application.
7. File formulation, process, package, and use patents before public disclosure.
8. Build a freedom-to-operate analysis around current Orange Book listings and live USPTO patent families.

The most defensible commercial concept is a stable, low-irritation formulation with a conventional patient experience. A complex package should be used only when it produces a measurable shelf-life or performance advantage.

Key Takeaways

• The commercial opportunity is in excipient and delivery-system differentiation, not in the old active ingredients.
• Erythromycin stability, benzoyl peroxide decomposition, and skin irritation are the core technical risks.
• Low-water gels, emulsion gels, and dual-chamber systems offer the strongest formulation-development paths.
• A conventional carbomer gel is easier to commercialize but is more exposed to generic competition.
• Patent value is likely to depend on narrow formulation, package, process, or performance claims.
• A 505(b)(2) strategy may be attractive for a differentiated formulation, while conventional equivalents may fit the ANDA pathway.
• FDA Orange Book and USPTO records must be reviewed for the specific reference product before launch or paragraph IV planning.
• The best licensing asset is a validated formulation platform supported by comparative stability and tolerability data.

FAQs

Can benzoyl peroxide and erythromycin be combined in one tube?

Yes, but the formulation must demonstrate acceptable chemical stability, active uniformity, microbiological quality, and shelf life. Separating the ingredients until use may improve stability but increases packaging and patient-use complexity.

Which preservative is best for an erythromycin and benzoyl peroxide gel?

No single preservative is universally preferred. Selection depends on water activity, pH, excipient compatibility, peroxide stability, and antimicrobial effectiveness testing. A reduced-preservative or preservative-free design may be commercially attractive if the formulation supports it.

Is a benzoyl peroxide and erythromycin product eligible for a generic drug application?

Potentially. A conventional product may be suitable for an ANDA if it meets the applicable requirements for pharmaceutical equivalence, bioequivalence, labeling, and product quality. Complex vehicles or delivery systems may require a different regulatory strategy.

Can a formulation patent cover the excipients alone?

Usually, the strongest claims cover the composition, concentration ranges, performance characteristics, or manufacturing process rather than an excipient in isolation. Conventional excipients require unexpected results or a technically distinctive combination to support meaningful patent protection.

Does benzoyl peroxide create a biosimilar risk?

No. Biosimilar pathways apply to biological products. Erythromycin and benzoyl peroxide are small-molecule active ingredients, so competitive entry would generally involve generic, hybrid, or other small-molecule regulatory pathways.

References

1. U.S. Food and Drug Administration. (2022). Nonsterile semisolid dosage forms: Scale-up and postapproval changes for semisolid drug products. https://www.fda.gov/

2. U.S. Food and Drug Administration. (n.d.-a). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (n.d.-b). 505(b)(2) applications. https://www.fda.gov/

4. U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (n.d.-d). Abbreviated new drug application submissions and patent certification. https://www.fda.gov/

6. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/